Tofacitinib Citrate

CAS号

540737-29-9

分子式

C22H28N6O8

主要靶点

Antifungal|Antibacterial|JAK|Apoptosis|Influenza Virus

仅限科研使用

Cat No : CM04909

Print datasheet

Synonyms

Inhibitor|Janus kinase|JAK|JAK2|JAK3|JAK1|Tasocitinib|Tasocitinib citrate|Tasocitinib Citrate|Tofacitinib (CP-690550) Citrate|Tofacitinib Citrate|Tofacitinib|柠檬酸托法替尼|枸橼酸托法替尼|CP690550 Citrate|CP-690550 Citrate|CP-690550 citrate|CP690550|CP-690550|CP 690550|CP 690550 Citrate|Fungal|inhibit|Influenza Virus|InfluenzaVirus|Bacterial|Apoptosis



产品信息

CAS号 540737-29-9
分子式 C22H28N6O8
主要靶点 Antifungal|Antibacterial|JAK|Apoptosis|Influenza Virus
主要通路 微生物学|表观遗传|蛋白酪氨酸激酶|干细胞|血管生成|JAK/STAT 信号通路|凋亡|微生物学|微生物学
分子量 504.49
纯度 99.75%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 store at low temperature,keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
别名 Inhibitor|Janus kinase|JAK|JAK2|JAK3|JAK1|Tasocitinib|Tasocitinib citrate|Tasocitinib Citrate|Tofacitinib (CP-690550) Citrate|Tofacitinib Citrate|Tofacitinib|柠檬酸托法替尼|枸橼酸托法替尼|CP690550 Citrate|CP-690550 Citrate|CP-690550 citrate|CP690550|CP-690550|CP 690550|CP 690550 Citrate|Fungal|inhibit|Influenza Virus|InfluenzaVirus|Bacterial|Apoptosis

靶点活性

JAK1:112 nM (cell free)|JAK2:20 nM (cell free)|JAK3:1 nM (cell free)

体内活性

CP-690,550治疗显著延长了与对照组相比的移植物存活时间。12只动物中有4只接受CP-690,550治疗(每个剂量组各两只)存活至研究结束,且肾功能正常,根据组织病理学判断只有轻度排斥反应[1]。用tofacitinib单药治疗小鼠能够抑制对由细菌蛋白质Pseudomonas exotoxin A衍生的免疫毒素以及模型抗原钥孔血蓝蛋白的抗体(Ab)反应。实验显示,在免疫后21天观察到对两种抗原IgG1滴度的千倍降低。Tofacitinib治疗还导致CD127+前B细胞数量减少[4]。

体外活性

虽然Tofacitinib (CP-690,550) 对JAK3的抑制作用极为强大(酶抑制效力为1 nM),但其对JAK2和JAK1的抑制作用分别低20至100倍。CP-690,550能以比对GM-CSF诱导的增殖30倍更强的效力抑制IL-2诱导的增殖。CP-690,550在使用鼠、猴或人细胞的混合淋巴细胞反应中展现出强大的抑制效果。与其作用机制一致,这些细胞活性与CP-690,550阻断IL-2诱导的JAK3及其关键底物STAT5的磷酸化能力相关[1]。在治疗含有人类野生型或V617F JAK2的鼠类因子依赖细胞Patersen-erythropoietin receptor (FDCP-EpoR)时,CP-690,550能抑制细胞增殖,其IC50分别为2.1 μg/ml和0.25 μg/ml。对JAK2(V617F)-阳性PV患者体外扩增的红细胞祖细胞进行CP-690,550治疗,表现出特异的抗增殖(IC50:0.2 μg/ml)和促凋亡活性[2]。Tofacitinib对JAK3的药理抑制作用与IMA在CML细胞中的抗肿瘤效果协同增强[3]。

溶解度

DMSO:55 mg/mL (109.02 mM)

细胞实验

Apoptotic cells were detected by flow cytometry using recombinant human Annexin-V conjugated with allophycocyanin. Briefly, after exposure to CP-690,550 for different periods of time, cells were washed in Ca2+-free PBS and resuspended in 100 μL of binding buffer (10 mM HEPES pH 7.4; 0.15 M NaC1; 5 mM KCl; 1 mM MgCl2; 1.8 mM CaCl2) to which Annexin-V-APC had been previously added. Cells were incubated for 20 min in the dark at room temperature, washed and resuspended in 0.3 mL binding buffer. Cells were analyzed on a FACSCalibur flow cytometer equipped with the Cell Quest Pro software [2].

动物实验

Mice received tofacitinib in PEG300 (100 mg/ml) or vehicle alone (PEG300) by osmotic pump infusion (Alzet Model 2004, 0.25 μl/hour, 28 days). Four days prior to immunization, mice were anesthetized and their dorsal surface was shaved. A one cm incision was made on the back to create a subcutaneous pocket and insert the pump. The incision site was closed with wound clips. Mice were injected weekly (i.p.) with SS1P recombinant immunotoxin (RIT; 5 μg/mouse) beginning on day 0; control mice received injections of saline alone. Every week before SS1P or vehicle immunization, ~50 μl of blood was drawn to obtain serum samples. Sera were stored at ?80°C until analyzed [4].

参考文献

1.Changelian PS, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003 Oct 31;302(5646):875-8.
2.Manshouri T, et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun;99(6):1265-73.
3.Yagi K, et al. Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia. Eur J Pharmacol. 2018 Apr 15;825:28-33.
4.Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193(1):48-55.
5.Flanagan ME, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010 Dec 23;53(24):8468-84.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2